Director, Global Value and Health Economics and Outcomes Research

Location: Remote/home-based; US-based candidates only. Listed location: Philadelphia, PA, US.

Base salary: $212,000–$318,000 per year, plus potential bonus, equity, and benefits.

Company

hirify.global is a global biopharmaceutical company developing medicines for serious diseases, with a portfolio spanning sleep disorders, epilepsy, oncology, and neuroscience.

What you will do

• Define and execute global payer evidence strategy and serve as the US HEOR lead for pipeline assets from Phase 2/3 through launch.
• Integrate payer, formulary, and HTA evidence requirements into clinical trial protocols, including comparators, endpoints, PROs, HRQoL, resource-use measures, and rare-disease evidence approaches.
• Lead health economic modeling, including conceptual models, cost-effectiveness analyses, budget impact models, Markov models, partitioned survival models, microsimulation, and probabilistic sensitivity analyses.
• Direct global core models, Global Value Dossiers, systematic literature reviews, US AMCP PIE dossiers, burden-of-illness dossiers, and US payer field tools.
• Partner with EU/INT HEOR teams on HTA strategies and analytical packages, including indirect comparisons, network meta-analyses, and country adaptations for JCA, NICE, G-BA, CADTH, and other bodies.
• Lead launch-readiness workstreams, real-world evidence studies, scientific publications, cross-functional governance, and mentorship of HEOR colleagues.

Requirements

• Master’s degree or higher, such as MSc, MS, MPH, or PhD, in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field.
• 7–10 years of HEOR, Global Value, or Health Economics experience in the biopharmaceutical industry or a top-tier HEOR consulting firm.
• Direct experience leading HEOR strategy and deliverables for pipeline assets, including Phase 2/3 protocol integration, endpoint development, and global launch readiness.
• Experience managing regional evidence trade-offs during Phase 2/3 protocol development and collaborating with Clinical Development, Commercial Development, Biostatistics, and regional HEOR teams.
• Experience launching at least two assets as a US HEOR lead or country-level HTA lead; above-country HEOR product leadership is preferred.
• Proven US pre-launch HEOR experience, including AMCP PIE dossiers, US budget impact models, payer field enablement, or significant exposure to these deliverables from a global role.
• Hands-on experience designing, overseeing, or adapting health economic models and working with data-sparse pipeline environments.
• Strong knowledge of US managed care and market access, global HTA frameworks, rare-disease evidence challenges, natural history studies, registries, external controls, surrogate endpoints, and specialized HTA pathways.
• Established HEOR or clinical publication record in peer-reviewed journals, or demonstrated HTA success; exceptional written and verbal communication and matrix leadership skills.

Nice to have

• Experience with neurology assets.
• Direct experience in rare disease, orphan drug, or highly specialized pipeline programs.

Culture & Benefits

• Remote/home-based role for US-based candidates.
• Full-time employment with medical, dental, and vision insurance.
• 401(k) retirement savings plan and flexible paid vacation.
• Potential discretionary annual cash bonus or incentive compensation and equity grants.
• Cross-functional, matrix-based collaboration across Clinical Development, Market Access, Medical Affairs, Regulatory Affairs, Commercial, and regional HEOR teams.